The Role of the Nuclear Factor-Kappa B (NF-κB) Pathway in SARS-CoV-2 Infection
Periyanaina Kesika,
Subramanian Thangaleela,
Natarajan Sisubalan,
Arumugam Radha,
Bhagavathi Sundaram Sivamaruthi,
Chaiyavat Chaiyasut
Affiliations
Periyanaina Kesika
Office of Research Administration, Chiang Mai University, Chiang Mai 50200, Thailand
Subramanian Thangaleela
Institute of Biotechnology, Department of Medical Biotechnology and Integrative Physiology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Chennai 602105, Tamil Nadu, India
Natarajan Sisubalan
Office of Research Administration, Chiang Mai University, Chiang Mai 50200, Thailand
Arumugam Radha
Department of Animal Science, School of Life Sciences, Bharathidasan University, Tiruchirappalli 620024, Tamil Nadu, India
Bhagavathi Sundaram Sivamaruthi
Office of Research Administration, Chiang Mai University, Chiang Mai 50200, Thailand
Chaiyavat Chaiyasut
Innovation Center for Holistic Health, Nutraceuticals, and Cosmeceuticals, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand
COVID-19 is a global health threat caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is associated with a significant increase in morbidity and mortality. The present review discusses nuclear factor-kappa B (NF-κB) activation and its potential therapeutical role in treating COVID-19. COVID-19 pathogenesis, the major NF-κB pathways, and the involvement of NF-κB in SARS-CoV-2 have been detailed. Specifically, NF-κB activation and its impact on managing COVID-19 has been discussed. As a central player in the immune and inflammatory responses, modulating NF-κB activation could offer a strategic avenue for managing SARS-CoV-2 infection. Understanding the NF-κB pathway’s role could aid in developing treatments against SARS-CoV-2. Further investigations into the intricacies of NF-κB activation are required to reveal effective therapeutic strategies for managing and combating the SARS-CoV-2 infection and COVID-19.
